Novartis drug receives FDA approval amid broader pharmaceutical industry updates
Novartis drug receives FDA approval amid broader pharmaceutical industry updates
Updated at: July 19, 2026 at 03:45 AM
Food and Drug Administration (FDA) granted traditional approval to Novartis’ Fabhalta (iptacopan) for treating adults with primary immunoglobulin A nephropathy (IgAN).
Fabhalta, a first-in-class complement inhibitor, is designed to slow the decline of kidney function in patients at high risk of disease progression.
The approval is based on findings from the Phase 3 APPLAUSE-IgAN trial, which showed that the medication slowed kidney function loss by 48% compared to a placebo.
IgAN is a chronic autoimmune condition that often leads to kidney failure, requiring dialysis or transplantation for many patients.
This milestone reflects Novartis's strategic push into kidney disease therapies, following their $3.2 billion acquisition of Chinook Therapeutics.
By targeting the underlying mechanisms of the disease rather than just managing symptoms, the industry is shifting toward more effective, personalized treatments.
To ensure accessibility, Novartis has introduced financial aid programs to assist eligible U.S. patients with costs.
This development represents a significant step forward for those living with chronic autoimmune kidney disease.
